Literature DB >> 15721587

Crystal structure of a cross-reaction complex between an anti-HIV-1 protease antibody and an HIV-2 protease peptide.

Pavlina Rezacova1, Jiri Brynda, Julien Lescar, Milan Fabry, Magda Horejsi, Irena Sieglova, Juraj Sedlacek, Graham A Bentley.   

Abstract

The monoclonal antibody 1696, elicited by HIV-1 protease, inhibits the activity of both HIV-1 and HIV-2 proteases with inhibition constants in the low nanomolar range. The antibody cross-reacts with peptides derived from the N-terminal region of both proteases. The crystal structure of the recombinant single-chain Fv fragment of 1696 complexed with an N-terminal peptide from the HIV-2 protease has been determined at 1.88A resolution. Interactions of the peptide with scFv1696 are compared with the previously reported structure of scFv1696 in complex with the corresponding peptide from HIV-1 protease. The origin of cross-reactivity of mAb1696 with HIV proteases is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721587     DOI: 10.1016/j.jsb.2004.11.009

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  4 in total

Review 1.  Targeting structural flexibility in HIV-1 protease inhibitor binding.

Authors:  Viktor Hornak; Carlos Simmerling
Journal:  Drug Discov Today       Date:  2006-12-20       Impact factor: 7.851

2.  Optimization of the crystallizability of a single-chain antibody fragment.

Authors:  Jana Škerlová; Vlastimil Král; Milan Fábry; Juraj Sedláček; Václav Veverka; Pavlína Rezáčová
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-11-14       Impact factor: 1.056

3.  Current and Novel Inhibitors of HIV Protease.

Authors:  Jana Pokorná; Ladislav Machala; Pavlína Rezáčová; Jan Konvalinka
Journal:  Viruses       Date:  2009-12-11       Impact factor: 5.048

4.  High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication.

Authors:  Sonald Duclair; Archana Gautam; Andrew Ellington; Vinayaka R Prasad
Journal:  Mol Ther Nucleic Acids       Date:  2015-02-17       Impact factor: 10.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.